Glejzer O, Sedzimirska M, Tomaszewska-Toporska B, Tomeczko J, Kołodziej J, Pacuszko T, Was A, Bocheńska J, Jaźwiec B, Klimczak A
Zespół Przeszczepiania Szpiku Kostnego, Szpital im. Kazimierza Dłuskiego.
Acta Haematol Pol. 1992;23(2 Suppl 1):49-59.
10 patients between the ages of 5 and 40 yrs with myeloid leukemia (4 acute, 6 chronic) in early (5 cases) or intermediate stage of the disease were given Cyclophosphamide and Busulfan (6 cases) or Cyclophosphamide, Busulfan and VP-16 (4 cases with CML) and bone marrow transplants from HLA-matched donors (in 9 cases from siblings and in one case from HLA phenotypically matched father). There was one transplant related death and 3 relapses in CML cases. In cases which relapsed GvHD was not observed. Altogether acute GvH and chronic GvHD was seen in 2 and 4 cases, respectively. All grafted cases with AML survive in continuous remission lasting more than 2 years (median 30.5 month).
10名年龄在5至40岁之间的髓系白血病患者（4例急性，6例慢性），处于疾病早期（5例）或中期，接受了环磷酰胺和白消安治疗（6例），或环磷酰胺、白消安和VP - 16治疗（4例慢性粒细胞白血病患者），并接受了来自HLA匹配供者的骨髓移植（9例来自兄弟姐妹，1例来自HLA表型匹配的父亲）。有1例与移植相关的死亡，慢性粒细胞白血病病例中有3例复发。在复发的病例中未观察到移植物抗宿主病（GvHD）。急性移植物抗宿主病（GvH）和慢性移植物抗宿主病分别见于2例和4例。所有接受移植的急性髓系白血病病例均持续缓解存活超过2年（中位时间30.5个月）。
